All In Biotech

Drug Trial Radar · NCT00136656

Treatment of Acute Pyelonephritis With Gram Negative Strains in Infants and Children Less Than 3 Years Old

Treatment of Acute Pyelonephritis With Gram Negative Strains in Infants and Children Less Than 3 Years Old. Cefixime PO 10d vs Ceftriaxone IV 4d Followed by Cefixime PO 6d. Multicenter, Randomised Trial of Equivalence.

Last checked: Nov 20, 2026Latest source record: Feb 12, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 700 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

700

Actual

Start

Jul 2005

Primary completion

Jun 2008

Study completion Feb 2009

Sponsor

Lead sponsor
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 29, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 1 month, up to 3 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to demonstrate the equivalence of the therapeutic efficacy of cefixime by mouth (PO) 10 days (d) and ceftriaxone intravenous route(IV) 4d followed by cefixime PO 6d on renal scars 6 months after a first acute pyelonephritis episode. The investigators hypothesize that treatment with cefixime PO will allow no more renal scars than intravenous route (IV) treatment of pyelonephritis in infants and children less than 3 years old, 6 months after the first episode. If it is true, treatment will no longer need hospitalisation and the advantages for children, families and the health system will be very important.

Conditions

  • Pyelonephritis

Interventions

  • antibioticDrug

    cephalosporine by oral route : cefixime

  • antibioticsDrug

    cephalosporine : ceftriaxone by intra venous route and cefixime by oral route

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Renal scars on dimercaptosuccinic acid (DMSA) renal scan at 6 monthsTime frame: between six and eight months

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Hopital de Bicetre

    Bicêtre, France

  • Hopital Pellegrin

    Bordeaux, France

  • Hôpital Ambroise Pare

    Boulogne, France

  • Hôpital Antoine Beclere

    Clamart, France

  • Chu de Limoges

    Limoges, France

  • La Timone

    Marseille, France

  • CHU NICE

    Nice, France

  • Saint Vincent de Paul

    Paris, France

  • Necker Enfants Malades

    Paris, France

  • Robert Debre

    Paris, France

  • Hôpital Armand Trousseau

    Paris, France

  • Hopital Andre Mignot

    Versailles, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.